compounded semaglutide crackdown news today The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new (Wegovy) weight-loss pill from the Counterfeit Ozempic Crackdown: Drugmakers Threaten

The company called Hims move illegal mass compounding that poses a significant risk to patient safety and said it will pursue legal and regulatory action to protect patients, our intellectual property and the integrity of the US goldstandard drug approval framework. A Novo spokesperson also labelled Hims mass compounding illegal and tied it to what the company described as a pattern of knockoff GLP1 products, as per CNBC

Araj-Khodaei, M., Ayati, M

GLP-1 medications may help improve lipid profiles in some patients, though effects vary significantly based on individual metabolic factors

Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review

The assay was performed as triplicates ( n = 3)

Laura Franzese, in Portland, Ore., learned about the licensing problem after spending $1,000 on a bulk order of tirzepatide from Zappy that arrived with Ousia labels